Urology · Daytona Beach, FL
NPI
1790949873
Since 2008
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
545 Health Blvd
Daytona Beach, FL, 32114
Phone (386) 239-8500
Groups this clinician bills Medicare through
Medicare paid, 2024
$543K
9,282 services
Medicare patients, 2024
602
Average age 76
Drug cost, 2024
$7.4M
2,158 prescriptions
Company payments, 2025
$5,731
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Evan Fynes was code J0897 (injection, denosumab, 1 mg), 4,380 times for 13 patients. In total Evan Fynes billed 9,282 services in 93 codes, and Medicare paid $543K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,380 | 13 | $20.41 | $89K |
| 81003 Clinical Chemistry | Office | 629 | 405 | $2.20 | $1,384 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 549 | 393 | $12.82 | $7,038 |
| 99214 Office E&M - Established | Office | 517 | 363 | $97.01 | $50K |
| 36415 Venipuncture Blood Collection | Office | 322 | 208 | $7.17 | $2,309 |
| 51798 Ultrasound - Nonspecific | Office | 274 | 226 | $8.55 | $2,343 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 250 | 59 | $51.04 | $13K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 166 | 22 | $140.23 | $23K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 97 | 36 | $38.80 | $3,764 |
| 99204 Office E&M - New | Office | 82 | 82 | $123.75 | $10K |
| 52000 Cystourethroscopy | Facility | 76 | 64 | $68.03 | $5,170 |
| 96372 Injection Administration | Office | 64 | 19 | $11.64 | $745 |
| 74176 CT/CTA - Abdomen and Pelvis | Office | 60 | 30 | $50.44 | $3,026 |
| 96402 Chemotherapy Administration | Office | 49 | 26 | $25.88 | $1,268 |
| 99222 Hospital E&M - Initial | Facility | 40 | 40 | $110.55 | $4,422 |
By year: 2022 $332K for 6,036 services; 2023 $400K for 8,009 services; 2024 $543K for 9,282 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 629 | 405 | $2.20 | $1,384 |
| 36415 Venipuncture Blood Collection | 322 | 208 | $7.17 | $2,309 |
Medicare prescription drug claims, 2024
In 2024, the drug Evan Fynes prescribed most often to Medicare patients was Tamsulosin Hcl, with 463 prescriptions and refills. In total Evan Fynes wrote 2,158 Medicare prescriptions that cost $7.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 463 | 1,297 | 217 | $9,400 |
| Erleada Apalutamide | 302 | 304 | 41 | $4.4M |
| Xtandi Enzalutamide | 177 | 177 | 22 | $2.4M |
| Orgovyx Relugolix | 172 | 172 | 23 | $516K |
| Finasteride Generic | 145 | 431 | 64 | $2,155 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 92 | 92 | 85 | $464 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 83 | 89 | 71 | $366 |
| Solifenacin Succinate Generic | 76 | 209 | 48 | $3,540 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 67 | 194 | 36 | $1,857 |
| Myrbetriq Mirabegron | 56 | 121 | 22 | $54K |
| Abiraterone Acetate Generic | 56 | 58 | 14 | $28K |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 46 | 63 | 40 | $1,049 |
| Cephalexin Generic | 41 | 48 | 33 | $367 |
| Testosterone Cypionate Generic | 37 | 92 | 19 | $1,930 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 34 | 92 | 14 | $1,114 |
Brand drugs: 738 claims; generic drugs: 1,420 claims; opioid claims: 112.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Evan Fynes $5,731 ($631 in general payments such as food, travel and fees and $5,100 for research) from 18 companies. The largest payer was Dendreon Pharmaceuticals LLC with $5,209.
| Company | Payments | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 3 | $5,209 |
| Pfizer Inc. PFE | 4 | $75.73 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $51.26 |
| Procept Biorobotics Corporation PRCT | 1 | $46.32 |
| Endo USA, Inc. | 2 | $42.83 |
| Janssen Biotech, Inc. JNJ | 2 | $42.48 |
| Merck Sharp & Dohme LLC MRK | 2 | $37.26 |
| Abbvie Inc. ABBV | 2 | $36.98 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $31.73 |
| Verity Pharmaceuticals Inc. | 2 | $28.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.